Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Withdrawn × nimotuzumab × Clear all

Phase

Phase 2 5 Phase 3 1 Phase 2/3 1 Phase 1 1

Status

Recruiting 5 Unknown 3 Completed 2 Withdrawn 1 Terminated 1 Not yet recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 1 Carcinoma 1

Interventions

Cisplatin 17 Carboplatin 11 Radiotherapy 10 Paclitaxel 9 Fluorouracil 8 Rituximab 7 Gemcitabine 7 Capecitabine 5 Vinorelbine 4 Nivolumab 4 Drug Therapy 4 Docetaxel 4 Bevacizumab 4 spartalizumab 3 pertuzumab 3 pembrolizumab 3 Trastuzumab 3 Standard of Care 3 Pemetrexed 3 Oxaliplatin 3 Etoposide 3 Dexamethasone 3 Cyclophosphamide 3 Cetuximab 3 Bendamustine Hydrochloride 3 parsaclisib 2 linrodostat 2 lenvatinib 2 human papillomavirus vaccine, L1 type 16, 18 2 fludarabine phosphate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01345084 2025-03-28

NICAP

Eurofarma Laboratorios S.A.

Phase 3 Withdrawn

Carcinoma, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡